Evonik Evonik

X

Find Devimistat manufacturers, exporters & distributors on PharmaCompass

PharmaCompass
API SUPPLIERS
API Suppliers

API Suppliers

0

US DMFs Filed

US DMFs Filed

0

CEP/COS Certifications

CEP/COS Certifications

0

JDMFs Filed

JDMFs Filed

0

Other Certificates

Other Certificates

0

Other Suppliers

Other Suppliers

0

API REF. PRICE (USD / KG)

0

INTERMEDIATES

0

DOSSIERS // FDF
USA (Orange Book)

USA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Uploaded Dossiers

Uploaded Dossiers

0

GLOBAL SALES (USD Million)

U.S. Medicaid

0

Annual Reports

0

EXCIPIENTS

0

PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

0

USFDA Exclusivities

0

DIGITAL CONTENT

Blog #PharmaFlow

0

News

REF STANDARD

EDQM

0

USP

0

JP

0

Other Listed Suppliers

0

SERVICES

0

Devimistat
Also known as: Cpi-613, 95809-78-2, Devimistat, Cpi 613, 6,8-bis(benzylsulfanyl)octanoic acid, Mls006010202
Molecular Formula
C22H28O2S2
Molecular Weight
388.6  g/mol
InChI Key
ZYRLHJIMTROTBO-UHFFFAOYSA-N
FDA UNII
E76113IR49

Devimistat is a racemic mixture of the enantiomers of a synthetic alpha-lipoic lipoic acid analogue with potential chemopreventive and antineoplastic activities. Although the exact mechanism of action is unknown, devimistat has been shown to inhibit metabolic and regulatory processes required for cell growth in solid tumors. Both enantiomers in the racemic mixture exhibit antineoplastic activity.
1 2D Structure

Devimistat

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
6,8-bis(benzylsulfanyl)octanoic acid
2.1.2 InChI
InChI=1S/C22H28O2S2/c23-22(24)14-8-7-13-21(26-18-20-11-5-2-6-12-20)15-16-25-17-19-9-3-1-4-10-19/h1-6,9-12,21H,7-8,13-18H2,(H,23,24)
2.1.3 InChI Key
ZYRLHJIMTROTBO-UHFFFAOYSA-N
2.1.4 Canonical SMILES
C1=CC=C(C=C1)CSCCC(CCCCC(=O)O)SCC2=CC=CC=C2
2.2 Other Identifiers
2.2.1 UNII
E76113IR49
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Cpi 613

2. Cpi-613

3. Cpi613

4. Devimistat

2.3.2 Depositor-Supplied Synonyms

1. Cpi-613

2. 95809-78-2

3. Devimistat

4. Cpi 613

5. 6,8-bis(benzylsulfanyl)octanoic Acid

6. Mls006010202

7. Cpi613

8. Schembl1062218

9. Mfcd22420826

10. E76113ir49

11. 6,8-bis[(phenylmethyl)thio]octanoic Acid

12. Octanoic Acid, 6,8-bis((phenylmethyl)thio)-

13. Octanoic Acid, 6,8-bis[(phenylmethyl)thio]-

14. Unii-e76113ir49

15. Devimistat [inn]

16. Devimistat [who-dd]

17. 6,8-bis(benzylthio)octanoicacid

18. Chembl3186849

19. Dtxsid70914807

20. Hms3656l06

21. Hms3873f13

22. 6,8-bis(benzylthio)-octanoic Acid

23. Bcp04663

24. Ex-a2043

25. Nsc766888

26. S2776

27. Akos025142095

28. Bcp9000552

29. Ccg-268505

30. Cs-0961

31. Db12109

32. Nsc-766888

33. Ncgc00344764-01

34. Ac-32929

35. As-16613

36. Hy-15453

37. Smr004701300

38. Sy234319

39. Bcp0726000030

40. 6,8-bis-benzylsulfanyl-octanoic Acid

41. Sw220297-1

42. (+/-)-6,8-bis(benzylthio)octanoic Acid

43. 6,8-bis(benzylthio)octanoic Acid, (+/-)-

44. J-518174

45. 6,8-bis(benzylthio)-octanoic Acid, >=98% (hplc)

46. Q27276958

47. Rac-(6r)-6,8-bis(benzylsulfanyl)octanoic Acid

2.4 Create Date
2008-04-28
3 Chemical and Physical Properties
Molecular Weight 388.6 g/mol
Molecular Formula C22H28O2S2
XLogP35.5
Hydrogen Bond Donor Count1
Hydrogen Bond Acceptor Count4
Rotatable Bond Count13
Exact Mass388.15307248 g/mol
Monoisotopic Mass388.15307248 g/mol
Topological Polar Surface Area87.9 Ų
Heavy Atom Count26
Formal Charge0
Complexity363
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count1
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY